Press Releases Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
2.3 ^USD	+5.50%		+12.75%	-23.08%

07/05	Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell	MT
07/05	Top Premarket Gainers	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®	14/05	GL
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®	14/05	AQ
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(4)	13/05	AQ
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	11/05	GL
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS	08/05	AQ
Esperion Therapeutics: Q1 Earnings Snapshot	07/05	AQ
Esperion Reports First Quarter 2024 Financial Results	07/05	GL
Esperion to Participate in Upcoming May Investor Conferences	29/04	GL
Esperion to Report First Quarter 2024 Financial Results on May 7	23/04	GL
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL Tablets in Diverse Populations Including Women, Hispanics, Latinx and Patients with Obesity	08/04	AQ
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	08/04	AQ
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	08/04	GL
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024	01/04	GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be presented at ACC.24	26/03	AQ
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference	26/03	GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	26/03	GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	26/03	AQ
Esperion - U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	25/03	AQ
Esperion - CHMP Issues Positive Opinions for both Bempedoic Acid and the Bempedoic Acid, Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events	25/03	AQ
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	23/03	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Press Releases

Filters